Ignite Creation Date:
2025-12-24 @ 11:54 PM
Ignite Modification Date:
2025-12-25 @ 9:50 PM
Study NCT ID:
NCT00343551
Status:
COMPLETED
Last Update Posted:
2017-02-23
First Post:
2006-06-22
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.
Sponsor:
Novartis
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2006-05
Start Date Type:
None
Primary Completion Date:
2007-01
Primary Completion Date Type:
ACTUAL
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2006-06-22
First Submit QC Date:
None
Study First Post Date:
2006-06-23
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-02-21
Last Update Post Date:
2017-02-23
Last Update Post Date Type:
ACTUAL